The rare risk of euglycemic ketoacidosis, while low, is higher in diabetic populations, particularly those also on SGLT2 inhibitors
Other companies, including Terns Pharmaceuticals (TERN-601), Structure Therapeutics (GSBR-1290), and Viking Therapeutics, have oral GLP-1 programs at earlier stages of development, but none has reached Phase 3 or generated the depth of clinical data available for orforglipron
Bromberg-martin, E
Nano-strategies for cancer treatment, focused on disrupting ROS, have undergone comprehensive development [13,14,15]
Clinical guidelines are evaluated and updated at least annually.Clinical guidelines are complex and intended for use by healthcare professionals
Brown adipose tissue thermogenesis in the resistance to and reversal of obesity: a potential new mechanism contributing to the metabolic benefits of proglucagon-derived peptides